Oncology

CIRCULATE-NORTH AMERICA: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

This study will evaluate what kind of chemotherapy to recommend to patients based on the presence or absence of circulating tumor DNA after surgery for colon cancer.

NCT06182774: A Phase III Non-Inferiority Randomized Controlled Trial of Fixed Duration versus Continuous Daratumumab Among Transplant Ineligible Older Adults with Newly Diagnosed Multiple Myeloma

The standard of care for individuals with myeloma who are not having a stem cell transplant is a treatment which includes the combination of drugs until they are no longer effective or cause major side effects. This study will assess whether a shorter duration of treatment for one of the drugs, daratumumab is as effective as continuous treatment.

SABR-COMET-3: Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic (1-3 Metastases) Cancer

Stereotactic Ablative Radiotherapy (SABR) is a modern Radiotherapy technique that delivers high doses of radiation to small tumor targets using highly conformal techniques. This method is non-invasive and administered on an outpatient basis. The purpose of this study is to compare the effect of SABR relative, to the standard of care alone on patient outcomes.

TAILOR: Multicohort Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia

The purpose of this study is to evaluate the efficacy and safety of the drug combination ibrutinib + venetoclax (I+V) compared to ibrutinib alone regimens in which dosing of ibrutinib is either proactively reduced or reactively modified in response to adverse events (AEs).

TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive and T3N0 Breast Cancer

The purpose of this study is to compare the effects on low risk breast cancer receiving usual care (including regional radiation therapy), with receiving no regional radiation therapy. It is of interest to know if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.

VIKTORIA-1: Gedatolisib Plus Fulvestrant with or Without Palbociclib vs Standard-of-Care for the Treatment of Patients with Advanced or Metastatic HR+/HER2- Breast Cancer

The efficacy and safety of gedatolisbib plus fulvestrant with or without palbociclib will be assessed in this study for the treatment of patients with advanced or metastatic Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER-) breast cancer following progression on or after CDK4/6 and aromatase inhibitor therapy.

BWEL: Randomized Phase III Trial Evaluation the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer

12 participants enrolled

CHALLENGE: A Phase III Study of the Impact of a Physical Activity Program on Disease-Free Survival in Patients with High Risk Stage II or Stage III Colon Cancer: A Randomized Controlled Trial

16 participants enrolled

COBRA: Phase II/III Study of Circulating tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients in Stage IIA Colon Cancer

12 participants enrolled

DYNAMIC-III: Circulating Tumor DNA Analysis Informing Adjuvant Chemotherapy in Stage III Colon Cancer: A Multicentre Phase II/III Randomised Controlled Study

13 participants enrolled

INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination with Chemotherapy in Induction/Maintenance or Post Progression in Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-driven Analysis

2 participants enrolled

KEYNOTE-564: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy

1 participant enrolled

LUMINA: A Prospective Cohort Study Evaluating Risk of Local Recurrence Following Breast Conserving Surgery and Endocrine Therapy in Low-Risk Luminal A Breast Cancer

15 participants enrolled

NCT01150045: A Phase III Trial of 6 versus 12 Treatment of Adjuvant Folfox Plus Celecoxib or Placebo For Patients With Resected Stage III Colon Cancer

10 participants enrolled

NCT02273375: A Phase III Prospective Double-Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 in Completely Resected Non-Small Cell Lung Cancer

1 participant enrolled

NCT02879318: A Randomized Phase II Trial of Gemcitabine and Nab-Paxlitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma

5 participants enrolled

PACE: International Randomised Study of Prostatectomy vs. Stereotactic Bosy Radiotherapy (SBRT) and Conventional Radiotherapy vs. SBRT for Early-Stage Organ-Confined Prostate Cancer

9 participants enrolled

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant along for hormone receptor positive (HR+)/human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

6 participants enrolled

PBS: Prostate Boost Irradiation with Stereotactic Body RT (SBRT).  A randomized phase II trial investigating Stereotactic Body Radiotherapy (SBRT) for prostate boost irradiation in the treatment of high-risk prostate cancer

54 participants enrolled

POLARGO: A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Safety and Efficacy of Polatuzumab Vedotin in Combination with Rituximab Plus Gemcitabine Plus Oxaliplatin (R-GEMOX) Versus R-GEMOX Along in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

1 participant enrolled

PROSPECT: A Phase II/III Trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision

6 participants enrolled

SABR-COMET-10: Stereotactic Ablative Radiotherapy for Comprehensive Treatment of 4-10 Oligometastatic Tumors

9 participants enrolled

SORENTO: A randomized, multi-center, open-label, active-controlled phase 3 trial to assess the efficacy and safety of octreotide subcutaneous depot (CAM2029) versus octreotide LAR or lanreotide ATG in patients with gastroenteropancreatic neuroendocrine tumors

1 participant enrolled

ALLTO: A Randomised, Multi-centre, Open-label, Phase III Study of Adjuvant Lapatinib, Trastuzumab, Their Sequence and Their Combination in Patients With HER2/ErbB2 Positive Primary Breast Cancer

1 participant enrolled

APHINITY: A Randomized Multicenter, Double-Blind, Placebo-Controlled Comparison of Chemotherapy Plus Trastuzumab Plus Placebo Versus Chemotherapy Plus Trastuzumab Plus Pertuzumab as Adjuvant Therapy in Patients With Operable HER2-Positive Primary Breast Cancer

1 participant enrolled

AROW: Accelerated Radiotherapy Outcomes in Women (Long Term Outcomes of a Randomized Trial of Breast Irradiation Schedules After Lumpectomy in Women With Node-Negative Breast Cancer)

85 participants enrolled

BL.5: A Phase III Study of Primary Chemotherapy in Locally Advanced Transitional Cell Carcinoma of the Bladder

3 participants enrolled

BOLERO-2: Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole

BR.6: A Clinical Trial of Early Versus Late Radiotherapy for Treatment of Limited Small Cell Carcinoma of the Lung

5 participants enrolled

BR.8: A Randomized Phase III Study of CODE Plus Thoracic Irradiation Versus Alternating CAV and EP for Extensive Stage Small Cell Lung Cancer

3 participants enrolled

BR.9: A Phase III Prospective Randomized Study of Combination Chemotherapy and Surgery Versus Radiotherapy for Stage IIIA Non-Small Cell Lung Cancer

2 participants enrolled

CL.1: A Phase III Comparison of Fludarabine Phosphate (NSC #312887) vs Chlorambucil vs Fludarabine Phosphate + Chlorambucil in Previously Untreated B-Cell Chronic Lymphocytic Leukemia

5 participants enrolled

CO.6: Intergroup Rectal Adjuvant Protocol: A Phase III Study

25 participants enrolled

CO.7: Phase III Clinical Trial of Chemotherapy with 5-Fluorouracil and L-leucovorin Following Potentially Curative Resection of Liver or Lung Metastases from Colorectal Cancer

1 participant enrolled

CO.9: A Phase III Evaluation of High-Dose Levamisole Plus 5FU and Leucovorin as Surgical Adjuvant Therapy for High Risk Colon Cancer

19 participants enrolled     

HD.5: Treatment of Advanced Hodgkin’s Disease a Randomized Phase III Trial Comparing ABVD versus MOPP/ABV Hybrid

5 participants enrolled

HORIZON III: First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX

LISA: Lifestyle Intervention Study in Adjuvant Treatment of Early Breast Cancer

25 participants enrolled

LUSTRE: A Randomized Trial of Medically-Inoperable Stage 1 Non-small Cell Lung Cancer Patients Comparing Stereotactic Body Radiotherapy Versus Conventional Radiotherapy

2 participants enrolled

MA.11: A Phase I Study of Escalating Epirubicin and Cyclophosphamide in Combination with 5-FU Using Granulocyte Colony Stimulating Factor Support in Premenopausal Women With Axillary Node Positive Operable Breast Cancer

10 participants enrolled

ME.8: A Double-Blind, Placebo-controlled, Randomized Phase III Study Comparing the Complete and Partial Response Rates of a Combination of Carmustine (BCNU), Dacarbazine (DTIC) and Cisplatin With and Without Tamoxifen in Patients with Metastatic Melanoma

MYSTIC: A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy or MEDI4736 Monotherapy Versus Standard of Care Platinum-Based Chemotherapy in First Line Treatment of Patients With Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC)

3 participants enrolled

MY.4: Etidronate Disodium (EHDP) Versus Placebo in the Treatment of Multiple Myeloma

1 participant enrolled

MY.5: Modified VAD (m-VAD-VINCRISTINE, ADRIAMYCIN, DEXAMETHASONE) in Primary Refractory and Relapsed Plasma Cell Myeloma

1 participant enrolled

MY.6: Clinical Trial of Interferon versus no Additional Treatment in Multiple Myeloma Patients Who Have Responded to Melphalan and Prednisone

14 participants enrolled

NCT00002542: Tamoxifen in Treating Women With High-Risk Breast Cancer

NCT00002550:  A Phase III Comparison Between Concurrent Chemotherapy Plus Radiotherapy and Concurrent Chemotherapy Plus Radiotherapy Followed by Surgical Resection for Stage IIIA (N2) Non-Small Cell Lung Cancer

2 participants enrolled

NCT00002570: A  Phase III Study of Immediate Versus Delayed Chemotherapy for Asymptomatic Advanced Colorectal Cancer

11 participants enrolled

NCT00002583: Vinorelbine + Cisplatin or No Further Therapy in Non-small Cell Lung Cancer That Has Been Surgically Removed

NCT00002678: Combination Chemotherapy in Treating Patients with Multiple Myeloma

NCT00002864: Tamoxifen With or Without Octreotide in Treating Postmenopausal Women With Stage I, Stage II, or Stage III Breast Cancer

NCT00002878: Combination Chemotherapy With or Without PSC 833 in Treating Patients With Relapsed or Refractory Multiple Myeloma

2 participants enrolled

NCT00003011: A Phase III Study of Marimastat in Patients with Small Cell Lung Cancer Following a Response to First Line Chemotherapy

6 participants enrolled

NCT00003032: High Dose Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Therapy in Treating Women With Metastatic or Recurrent Breast Cancer

NCT00003140: Letrozole After Tamoxifen in Treating Women With Breast Cancer

NCT00003422: Radiation Therapy Before Surgery Compared With Chemotherapy Plus Radiation After Surgery in Treating Patients With Rectal Cancer That Can Be Surgically Removed

NCT00003653: Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer

NCT00003833: Genetic Study in Patients With Stage II or Stage III Colon Cancer

NCT00003892: ISIS 5132 in Treating Patients With Metastatic or Recurrent Ovarian Cancer

NCT00004179: Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma

NCT00004934: A Randomized Trial of Paclitaxel/Epirubicin/Carboplatin Combination (TEC) Versus Paclitaxel/Carboplatin (TC) in the Treatment of Women With Advanced Ovarian Cancer

2 participants enrolled

NCT00005957: Radiation Therapy in Treating Women Who Have Undergone Surgery for Early-Stage Invasive Breast Cancer

NCT00006229: Paclitaxel + Carboplatin With/​ut BMS-275291 in Advanced or Metastatic Non-small Cell Lung Cancer

NCT00006890: Thalidomide and Prednisone Following Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

NCT00014222: Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer

NCT00026338: Gemcitabine With/​Out Erlotinib in Unresectable Locally Advanced/​Metastatic Pancreatic Cancer

NCT00028743: Combination Chemotherapy Regimens in Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

NCT00045032: Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer (HERA)

NCT00049075: A Phase II Study of Oral Fludarabine Phosphate in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia

2 participants enrolled

NCT00052910: Phase III Intergroup Trial of Adjuvant Chemoradiation After Resection of Gastric or Gastroesophageal Adenocarcinoma

1 participant enrolled

NCT00056446: Study of Oxaliplatin/​5-FU/​Leucovorin Plus Vatalanib Versus Oxaliplatin/​5-FU/​Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer

NCT00066313: A Phase II Study Of ZD6474 Or Placebo In Small Cell Lung Cancer Patients Who Have Complete Or Partial Response To Induction Chemotherapy +/- Radiation Therapy

7 participants enrolled

NCT00066573: Exemestane or Anastrozole in Treating Postmenopausal Women Who Have Undergone Surgery for Primary Breast Cancer

NCT00079066: A Phase III Randomized Study of Cetuximab (Erbitux™, C225) and Best Supportive Care Versus Best Supportive Care in Patients With Pretreated Metastatic Epidermal Growth Factor Receptor (EGFR)-Positive Colorectal Carcinoma

NCT00156052: Hypofractionated Radiotherapy Post-Lumpectomy in Women With Node Negative Breast Cancer

NCT00201929: A Decision Aid for Women With Early Stage Breast Cancer

NCT00238316: A Randomized Feasibility Study of Letrozole in Postmenopausal Women at Increased Risk for Development of Breast Cancer as Evidenced by High Breast Density

8 participants enrolled

NCT00245154: Paclitaxel + Carboplatin With/​Out Cediranib Maleate in Stage III or Stage IV Non-Small Cell Lung Cancer

NCT00265850: Cetuximab and/ or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer

NCT00640471: Cetuximab With or Without Brivanib in Treating Patients With K-Ras Wild Type Tumours and Metastatic Colorectal Cancer

NCT00667251: Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/​Neu-Positive Metastatic Breast Cancer

NCT00754845: Letrozole in Breast Cancer Who Have Received 5 Years of Aromatase Inhibitor Therapy

NCT00795340: Cediranib, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT01000025: PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic Cancer

NCT01101438: A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer

36 participants enrolled

NCT01286233: Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer

9 participants enrolled

NCT01423890: A Prospective Cohort Study to Evaluate the Oncotype DX® Test in Early Stage Breast Cancer (ONCOTYPEDX)

NCT01526135: Multicentric Randomized Phase III Trial Comparing Adjuvant Chemotherapy With Gemcitabine Versus 5-fluorouracil, Leucovorin, Irinotecan and Oxaliplatin (mFolfirinox) in Patients With Resected Pancreatic Adenocarcinoma

4 participants enrolled

NCT02630693: Randomized Phase II Study Comparing Two Different Schedules of Palbociclib Plus Second Line Endocrine Therapy in Women With Estrogen Receptor Positive, HER2 Negative Advanced/Metastatic Breast Cancer

4 participants enrolled

NCT03057106: A Randomized Trial of Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic (Stage IV) Squamous or Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

3 participants enrolled

OV.9: A Multicentre, Randomized Comparative Study of Taxol in Platinum Treated Ovarian Cancer (High vs. Low Dose; Long vs. Short Infusion)

1 participant enrolled

OV.11: A Phase II Trial of Intraperitoneal Cisplatin and Intravenous and Intraperitoneal Paclitaxel in Women with Optimally-Debulked Stage III Epithelial Ovarian Cancer

1 participant enrolled

OV.12: A Phase III Comparison of BAY 12-9566 versus Placebo as Consolidation After Standard Chemotherapy in Patients with Epithelial Ovarian Cancer

4 participants enrolled

PA.1: A Phase III Study of Bay 12-9566 Versus Gemcitabine in Patients with Advanced or Metastatic Adenocarcinoma of the Pancreas

2 participants enrolled

PALOMA-3: Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure

RAPID:  Randomized Trial of Accelerated Partial Breast Irradiation

36 participants enrolled

SC.7: A Randomized Double-Blind Efficacy, Safety and Pharmacokinetic Study of Six Doses of the Antiemetic BMY-25801 and Methylprednisone Along Out-Patients Receiving Moderately Emetogenic Chemotherapy

SC.8: A Double-Blind Comparator Study for the Prophylactic Use of Granisetron Both Alone and in Combination With Dexamethasone Over a 7 Day Period in Controlling Nausea and Vomiting Associated With High Dose Cisplatin Therapy in Patients With Malignant Disease

SC.9: An Assessment of the Effect of Schedule and Maintenance on the Antiemetic Efficacy and Safety of Ondansetron Combined With Dexamethasone as Acute and Maintenance Therapy in Patients Receiving Moderately Emetogenic Chemotherapy

SC.11: A Phase III Double-Blind Comparison of Dolasetron Mesylate With Ondansetron and an Evaluation of the Additive Role of Dexamethasone in the Prevention of Acute (IV) and Delayed (Oral) Emesis Due to Moderately Emetogenic Chemotherapy